A phase III randomized trial evaluating alirocumab 300 mg every 4 weeks as monotherapy or add-on to statin: ODYSSEY CHOICE I

Atherosclerosis

Volumn 254, Issue , 2016, Pages 254-262

  Roth, Eli M ^a   Moriarty, Patrick M ^b   Bergeron, Jean ^c   Langslet, Gisle ^d   Manvelian, Garen ^e   Zhao, Jian ^f   Baccara Dinet, Marie T ^g   Rader, Daniel J ^h  

^a Sterling Research Group   (United States)

^b UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^c LAVAL UNIVERSITY   (Canada)

^d OSLO UNIVERSITY HOSPITAL   (Norway)

^e REGENERON PHARMACEUTICALS INC   (United States)

^f REGENERON PHARMACEUTICALS INC   (United States)

^g SANOFI   (France)

^h UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Alirocumab; Cardiovascular risk; LDL C; PCSK9; Phase III; Placebo controlled; Randomized

Indexed keywords

ALANINE AMINOTRANSFERASE; ALIROCUMAB; ASPARTATE AMINOTRANSFERASE; ATORVASTATIN; CREATINE KINASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; ROSUVASTATIN; SIMVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MONOCLONAL ANTIBODY; PCSK9 PROTEIN, HUMAN; PROPROTEIN CONVERTASE 9;

ADD ON THERAPY; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BRAIN ISCHEMIA; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; COMBINATION DRUG THERAPY; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DISORDERS OF HIGHER CEREBRAL FUNCTION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; LOADING DRUG DOSE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MONOTHERAPY; MULTICENTER STUDY; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; UNSTABLE ANGINA PECTORIS; AGED; BLOOD; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DRUG ADMINISTRATION; FOLLOW UP; GENOTYPE; METABOLISM; PATHOLOGY; TREATMENT OUTCOME;

AGED; ANTIBODIES, MONOCLONAL; ATORVASTATIN CALCIUM; CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; PROPROTEIN CONVERTASE 9; SIMVASTATIN; TREATMENT OUTCOME;

EID: 84994357535     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2016.08.043     Document Type: Article

References (20)

1. [1] Kereiakes, D.J., Robinson, J.G., Cannon, C.P., et al. Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: the ODYSSEY COMBO I study. Am. Heart J. 169 (2015), 906–915.
2. [2] Roth, E.M., Taskinen, M.R., Ginsberg, H.N., et al. Monotherapy with the PCSK9 inhibitor alirocumab vs. ezetimibe in patients with hypercholesterolemia: results of a 24 week, double-blind, randomized Phase 3 trial. Int. J. Cardiol. 176 (2014), 55–61.
3. [3] Bays, H., Gaudet, D., Weiss, R., et al. Alirocumab as add-on to atorvastatin vs. other lipid treatment strategies: ODYSSEY OPTIONS I randomized trial. J. Clin. Endocrinol. Metab. 100 (2015), 3140–3148.
4. [4] Robinson, J.G., Farnier, M., Krempf, M., et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N. Engl. J. Med. 372 (2015), 1489–1499.
5. [5] Stein, E.A., Gipe, D., Bergeron, J., et al. Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial. Lancet 380 (2012), 29–36.
6. [6] McKenney, J.M., Koren, M.J., Kereiakes, D.J., et al. Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy. J. Am. Coll. Cardiol. 59 (2012), 2344–2353.
7. [7] Stein, E.A., Mellis, S., Yancopoulos, G.D., et al. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. N. Engl. J. Med. 366 (2012), 1108–1118.
8. [8] Rey, J., Poitiers, F., Paehler, T., et al. Randomized, partial blind study of the pharmacodynamics, pharmacokinetics and safety of multiple subcutaneous doses of alirocumab, a fully human monoclonal antibody to proprotein convertase subtilisin/kexin type 9, administered every 4 weeks alone or in combination with ezetimibe or fenofibrate in healthy subjects. J. Am. Coll. Cardiol., 63, 2014, A1375.
9. [9] Seidah, N.G., Awan, Z., Chretien, M., et al. PCSK9: a key modulator of cardiovascular health. Circ. Res. 114 (2014), 1022–1036.
10. [10] Miyoshi, T., Nakamura, K., Doi, M., et al. Impact of ezetimibe alone or in addition to a statin on plasma PCSK9 concentrations in patients with type 2 Diabetes and hypercholesterolemia: a pilot study. Am. J. Cardiovasc. Drugs 15 (2015), 213–219.
11. [11] McKenney, J.M., Swergold, G.D., DiCioccio, T., et al. Dynamics between the Monoclonal Antibody SAR236553/REGN727, Proprotein Convertase Subtilisin/kexin Type 9 (PCSK9) and Low-density Lipoprotein Cholesterol (LDL-C) Levels. In, 81st European Atherosclerosis Society (EAS) Congress, Lyon, France, 2013.
12. [12] Stroes, E., Guyton, J.R., Farnier, M., et al. Alirocumab in Patients with Hypercholesterolemia Not on Statin Therapy: the ODYSSEY CHOICE II Study. 2015 http://www.eventure-online.com/eventure/publicAbstractView.do?id=259147&congressId=8753 [Accessed 06.05.16].
13. [13] Grundy, S.M., Cleeman, J.I., Merz, C.N., et al. Implications of recent clinical trials for the national cholesterol education Program adult treatment Panel III guidelines. Circulation 110 (2004), 227–239.
14. [14] Moriarty, P.M., Jacobson, T.A., Bruckert, E., et al. Efficacy and safety of alirocumab, a monoclonal antibody to PCSK9, in statin-intolerant patients: design and rationale of ODYSSEY ALTERNATIVE, a randomized phase 3 trial. J. Clin. Lipidol. 8 (2014), 554–561.
15. [15] Reiner, Z., Catapano, A.L., DB, G., et al. ESC/EAS guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European atherosclerosis Society (EAS). Eur. Heart J. 32 (2011), 1769–1818.
16. [16] Robinson, J.G., Colhoun, H.M., Bays, H.E., et al. Efficacy and safety of alirocumab as add-on therapy in high-cardiovascular-risk patients with hypercholesterolemia not adequately controlled with atorvastatin (20 or 40 mg) or rosuvastatin (10 or 20 mg): design and rationale of the ODYSSEY OPTIONS Studies. Clin. Cardiol. 37 (2014), 597–604.
17. [17] Kastelein, J.J., Robinson, J.G., Farnier, M., et al. Efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolemia not adequately controlled with current lipid-lowering therapy: design and rationale of the ODYSSEY FH studies. Cardiovasc Drugs Ther. 28 (2014), 281–289.
18. [18] Colhoun, H.M., Robinson, J.G., Farnier, M., et al. Efficacy and safety of alirocumab, a fully human PCSK9 monoclonal antibody, in high cardiovascular risk patients with poorly controlled hypercholesterolemia on maximally tolerated doses of statins: rationale and design of the ODYSSEY COMBO I and II trials. BMC Cardiovasc. Disord., 14, 2014, 121.
19. [19] Guo, Y.L., Liu, J., Xu, R.X., et al. Short-term impact of low-dose atorvastatin on serum proprotein convertase subtilisin/kexin type 9. Clin. Drug Investig. 33 (2013), 877–883.
20. [20] Dubuc, G., Chamberland, A., Wassef, H., et al. Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia. Arterioscler. Thromb. Vasc. Biol. 24 (2004), 1454–1459.